Pantoprazole and Docetaxel for Men With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer Clinical Trial

Official title:

Pantoprazole and Docetaxel for Men With Metastatic Castration-Resistant Prostate Cancer - a Single Arm Phase II Clinical Trial With a Predefined Reference Group (PANDORA)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01748500
• Other study ID #: PANDORA
• Secondary ID: 12-0388-C
• Status: Completed
• Phase: Phase 2
• Start date: January 2013
• Est. completion date: March 2021

Study information

• Verified date: March 2021
• Source: University Health Network, Toronto
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main objectives of this trial are:

1. To assess the activity and safety of pantoprazole and docetaxel (with prednisone) in men with metastatic CRPC who have not received prior chemotherapy.

2. To evaluate archival prostate cancer tissue of men included in the clinical trial for evidence of autophagy using IHC for LC3B, ATG5, p62 as well as ERG.

3. To evaluate pharmacokinetic interactions of pantoprazole with docetaxel.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: March 2021
• Est. primary completion date: March 2021
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age =18yrs

• ECOG performance status =2

• Histologically or cytologically confirmed adenocarcinoma of the prostate

• Clinical or radiological evidence of metastatic disease

• Disease progression while receiving androgen deprivation therapy with an increase in PSA of 25% or greater over nadir value measured on 3 consecutive occasions at least 1 week apart

• Antiandrogen therapy must have been stopped at least 4 weeks prior to start of trial treatment (6 weeks in the case of bicalutamide or nilutamide)if there was a reduction in serum PSA after this therapy was initiated

• Baseline serum prostate-specific antigen (PSA)=10ng/ml

• Total testosterone <50 ng/dL (<1.7 nmol/L)

• Adequate hematologic values: neutrophil count =1,500/mm3, platelet =100,000/mm3, hemoglobin =10.0 g/dl

• Adequate hepatic and renal function: total bilirubin level =1.5 x ULN (unless secondary to documented Gilbert's disease); ALT,AST, and creatinine =1.5 x ULN

• Ability to understand and to sign consent for the study

Exclusion Criteria:

• Prior treatment for prostate cancer with chemotherapy or radioisotopes

• History of another cancer within the preceding five years (except basal or squamous-cell skin cancer or adequately treated superficial bladder cancer)

• Known or suspected brain or leptomeningeal metastases

• Symptomatic peripheral neuropathy of grade 2 or higher

• Major surgery within 4 weeks of start of trial treatment

• Radiotherapy to =25% of the bone marrow and any radiotherapy within 4 weeks of start of trial treatment

• Known hypersensitivity to trial treatment or hypersensitivity to any of its components

• Any concomitant drugs contraindicated for use with the trial treatment

• Any serious underlying medical condition which could impair the ability of the patient to participate in the trial

• Any psychological, familial, sociological or other patient related factors that might preclude compliance with the study protocol

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• Pantoprazole

Locations

Country	Name	City	State
Canada	Princess Margaret Cancer Centre	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
University Health Network, Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Confirmed PSA response	The primary endpoint is met if PSA falls to =50% of baseline, maintained for =3 weeks.	20 months